Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.
Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.
Clinipace has signed a far-reaching deal with biotech Karyopharm, agreeing to handle a host of studies under a preferred provider arrangement.
Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.
Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.
AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.
Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant.
WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.
Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.
CRO BioClinica said it inked two long-term deals with major drugmakers totaling $30 million, touting its eClinical technology as driving sponsor interest.
North Carolina CRO Rho has signed up to help the U.S. government's Biomedical Advanced Research and Development Authority design and conduct clinical trials for treatments that protect against bioterrorism and other public health emergencies, getting in line for as much as $100 million over 5 years.
A month removed from a $915 million buyout deal, CRO Medpace has signed on to help biotech NephroGenex get through Phase III with its promising kidney disease candidate.
Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.
CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.
Global CRO Covance is expanding its heft in biologics development, plotting to double its capacity over the next 5 years.
Amid the prolonged bull market for life sciences IPOs, a handful of European firms are lining up to test the waters in Europe, including CMO giant Recipharm, which is planning to stage a $142 million offering.
Contract outfit TKL Research has opened a new early-phase-focused clinic in Northern New Jersey, looking to capitalize on demand for Phase I services as it expands its footprint.
AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Germany's Evotec has signed a deal to buy up a biopharma asset management company and get its hands on some promising drug candidates, broadening its novel approach to the CRO game by adding some unpartnered assets to its stable of collaborations.
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.